Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil



Ceftazidime-avibactam, Enterobacterales, Carbapenemase, Resistance


Carbapenem-resistant Enterobacterales (CRE) are a subject of global concern as limited therapeutic options are available. New combinations of β-lactams and β-lactamase inhibitors, such as ceftazidime-avibactam (CAZ-AVI), have recently been approved in Brazil for the treatment of CRE infections. Cases of resistance during treatment or even without previous CAZ-AVI use have been published and it is worrisome in scenarios where KPC-producing Gram-negative bacilli are endemic, as in Brazil. We aimed to assess CAZ-AVI susceptibility among a CRE population recovered from hospitalized patients in Southern Brazil from 2015 to 2021. CAZ-AVI minimal inhibitory concentration (MIC) was determined by antibiotic gradient strips. All the 238 evaluated KPC-producing Enterobacterales were susceptible to CAZ-AVI (MIC = 0.25 to 8 µg/mL), with seven isolates presenting borderline MICs (8 µg/mL). Considering the clinical importance of this new antibiotic in Brazil, we emphasize the importance of surveillance studies to eventually detect resistance phenotypes or even increasing CAZ-AVI MICs.


Não há dados estatísticos.




Como Citar

Kehl Moreira N, da Silva Collar G, Lamb Wink P, Luís Barth A, Caierão J. Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil. Clin Biomed Res [Internet]. 29º de novembro de 2023 [citado 24º de fevereiro de 2024];43(3). Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/128523

Artigos mais lidos pelo mesmo(s) autor(es)